|
US11385233B2
(en)
|
2015-03-05 |
2022-07-12 |
Autolus Limited |
Methods of depleting malignant T-cells
|
|
US20230027993A1
(en)
|
2014-03-05 |
2023-01-26 |
Autolus Limited |
Methods
|
|
GB201403972D0
(en)
|
2014-03-06 |
2014-04-23 |
Ucl Business Plc |
Chimeric antigen receptor
|
|
EA201792573A1
(ru)
|
2015-05-21 |
2018-04-30 |
Харпун Терапьютикс, Инк. |
Триспецифические связанные белки и способы их применения
|
|
JP7101621B2
(ja)
|
2016-05-20 |
2022-07-15 |
ハープーン セラピューティクス，インク． |
単一ドメイン血清アルブミン結合タンパク質
|
|
SG11201907299XA
(en)
|
2017-02-08 |
2019-09-27 |
Dragonfly Therapeutics Inc |
Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer
|
|
CN108395482B
(zh)
|
2017-02-08 |
2021-02-05 |
西比曼生物科技（香港）有限公司 |
一种靶向cd20抗原嵌合抗原受体的构建及其工程化t细胞的活性鉴定
|
|
IL268755B2
(en)
|
2017-02-20 |
2025-12-01 |
Dragonfly Therapeutics Inc |
Proteins that bind her2, nkg2d, and cd16
|
|
JP2020530554A
(ja)
|
2017-07-20 |
2020-10-22 |
シートムエックス セラピューティクス，インコーポレイテッド |
活性化抗体の特性を定性的および／または定量的に分析する方法およびその使用
|
|
KR102172092B1
(ko)
|
2017-09-19 |
2020-10-30 |
주식회사 엘지화학 |
열가소성 수지 조성물, 이의 제조방법 및 성형품
|
|
HRP20241268T1
(hr)
|
2017-10-13 |
2024-12-06 |
Harpoon Therapeutics, Inc. |
Trispecifični proteini i postupci primjene
|
|
IL315737A
(en)
|
2017-10-13 |
2024-11-01 |
Harpoon Therapeutics Inc |
B-cell maturation antigen-binding proteins
|
|
JP2021500552A
(ja)
*
|
2017-10-20 |
2021-01-07 |
ナントバイオ，インコーポレイテッド |
膀胱癌免疫療法のモニタリング方法
|
|
DK3749346T3
(da)
|
2018-02-08 |
2024-09-09 |
Dragonfly Therapeutics Inc |
Antistof variable domænekombinationer rettet mod nkg2d-receptoren
|
|
EA202091887A1
(ru)
|
2018-02-08 |
2020-10-23 |
Драгонфлай Терапьютикс, Инк. |
Комбинированная терапия рака с применением мультиспецифических связывающих белков, которые активируют естественные клетки-киллеры
|
|
CN111989108B
(zh)
*
|
2018-02-13 |
2024-07-16 |
嵌合体生物工程公司 |
利用rna去稳定元件协调基因表达
|
|
WO2019164930A1
(en)
|
2018-02-20 |
2019-08-29 |
Dragonfly Therapeutics, Inc. |
Multi-specific binding proteins that bind cd33, nkg2d, and cd16, and methods of use
|
|
US20220025037A1
(en)
*
|
2018-04-03 |
2022-01-27 |
Dragonfly Therapeutics, Inc. |
Antibody variable domains targeting dll3, and use thereof
|
|
CA3095920A1
(en)
*
|
2018-04-10 |
2019-10-17 |
Amgen Inc. |
Chimeric receptors to dll3 and methods of use thereof
|
|
BR112020020604A2
(pt)
|
2018-04-11 |
2021-01-12 |
Inhibrx, Inc. |
Construções de polipeptídeo multiespecífico tendo ligação restrita de cd3 e métodos e usos relacionados
|
|
CA3097193A1
(en)
*
|
2018-05-08 |
2019-11-14 |
Phanes Therapeutics, Inc. |
Anti-dll3 antibodies and uses thereof
|
|
KR20210020903A
(ko)
|
2018-05-14 |
2021-02-24 |
하푼 테라퓨틱스, 인크. |
면역글로불린 분자의 조건부 활성화를 위한 결합 모이어티
|
|
WO2020023553A1
(en)
|
2018-07-24 |
2020-01-30 |
Inhibrx, Inc. |
Multispecific polypeptide constructs containing a constrained cd3 binding domain and a receptor binding region and methods of using the same
|
|
WO2020033630A1
(en)
|
2018-08-08 |
2020-02-13 |
Dragonfly Therapeutics, Inc. |
Multi-specific binding proteins that bind bcma, nkg2d and cd16, and methods of use
|
|
EA202091888A1
(ru)
|
2018-08-08 |
2020-10-23 |
Драгонфлай Терапьютикс, Инк. |
Вариабельные домены антител, нацеленные на рецептор nkg2d
|
|
US12378318B2
(en)
|
2018-08-08 |
2025-08-05 |
Dragonfly Therapeutics, Inc. |
Proteins binding NKG2D, CD16 and a tumor-associated antigen
|
|
EP3850088A4
(en)
|
2018-09-07 |
2023-07-19 |
Beam Therapeutics, Inc. |
Compositions and methods for improving base editing
|
|
KR20210055733A
(ko)
|
2018-09-07 |
2021-05-17 |
빔 테라퓨틱스, 인크. |
핵염기 편집 시스템을 전달하기 위한 조성물 및 방법
|
|
WO2020061482A1
(en)
|
2018-09-21 |
2020-03-26 |
Harpoon Therapeutics, Inc. |
Egfr binding proteins and methods of use
|
|
EP3864045A2
(en)
*
|
2018-10-11 |
2021-08-18 |
Inhibrx, Inc. |
Dll3 single domain antibodies and therapeutic compositions thereof
|
|
US20230158071A1
(en)
*
|
2018-12-07 |
2023-05-25 |
Crage Medical Co., Limited |
Tumor combined immunotherapy
|
|
WO2020168122A1
(en)
|
2019-02-13 |
2020-08-20 |
Beam Therapeutics Inc. |
Modified immune cells having adenosine deaminase base editors for modifying a nucleobase in a target sequence
|
|
WO2020180591A1
(en)
|
2019-03-01 |
2020-09-10 |
Allogene Therapeutics, Inc. |
Dll3 targeting chimeric antigen receptors and binding agents
|
|
US20220145397A1
(en)
*
|
2019-03-08 |
2022-05-12 |
Oncolab Diagnostics Gmbh |
Cancer diagnosis and prognosis
|
|
CA3132202A1
(en)
*
|
2019-04-08 |
2020-10-15 |
Phanes Therapeutics, Inc. |
Humanized anti-dll3 chimeric antigen receptors and uses thereof
|
|
US12516128B2
(en)
|
2019-05-14 |
2026-01-06 |
Harpoon Therapeutics, Inc. |
EpCAM binding proteins and methods of use
|
|
CA3146019A1
(en)
*
|
2019-07-17 |
2021-01-21 |
Nanjing Legend Biotech Co., Ltd. |
Anti-dll3 chimeric antigen receptors and uses thereof
|
|
EP4013431A4
(en)
*
|
2019-08-18 |
2024-05-01 |
Chimera Bioengineering, Inc. |
Combination therapy with gold controlled transgenes
|
|
EP4034138A4
(en)
|
2019-09-27 |
2024-07-31 |
Beam Therapeutics, Inc. |
COMPOSITIONS AND METHODS FOR THE TREATMENT OF LIQUID CANCERS
|
|
CN115380047A
(zh)
|
2020-01-29 |
2022-11-22 |
印希比股份有限公司 |
Cd28单结构域抗体及其多价和多特异性构建体
|
|
EP4097135A4
(en)
*
|
2020-01-31 |
2024-07-03 |
Gensun Biopharma Inc. |
Bispecific t cell engagers
|
|
US12486331B2
(en)
|
2020-01-31 |
2025-12-02 |
Gensun Biopharma Inc. |
Bispecific T cell engagers
|
|
US12606635B2
(en)
|
2020-03-12 |
2026-04-21 |
Nanjing Legend Biotech Co., Ltd. |
Glypican-2-binding moieties, chimeric antigen receptors and uses thereof
|
|
CN113402612A
(zh)
|
2020-03-17 |
2021-09-17 |
西比曼生物科技（香港）有限公司 |
靶向cd19和cd20的联合嵌合抗原受体及其应用
|
|
CN113444172A
(zh)
*
|
2020-03-25 |
2021-09-28 |
兴盟生物医药(苏州)有限公司 |
金黄色葡萄球菌α-毒素特异性抗体及其应用
|
|
MX2022013944A
(es)
|
2020-05-06 |
2022-11-30 |
Dragonfly Therapeutics Inc |
Proteinas que se unen al receptor activador de celulas asesinas naturales grupo 2 miembro d (nkg2d), cumulo de diferenciacion (cd16) y miembro a de la familia de dominios de lectina tipo c 12 (clec12a).
|
|
AU2021347359A1
(en)
|
2020-09-25 |
2023-05-18 |
Beam Therapeutics Inc. |
Fratricide resistant modified immune cells and methods of using the same
|
|
AU2021372988A1
(en)
*
|
2020-11-06 |
2023-06-22 |
Board Of Regents, The University Of Texas System |
Methods and systems for classification and treatment of small cell lung cancer
|
|
JP2024508894A
(ja)
|
2021-03-03 |
2024-02-28 |
ドラゴンフライ セラピューティクス， インコーポレイテッド |
Ｎｋｇ２ｄ、ｃｄ１６、及び腫瘍関連抗原に結合する多特異性結合タンパク質を使用して癌を治療する方法
|
|
CN117083067A
(zh)
*
|
2021-04-02 |
2023-11-17 |
南京传奇生物科技有限公司 |
工程化的免疫细胞及其用途
|
|
JP2024532486A
(ja)
*
|
2021-09-02 |
2024-09-05 |
メモリアル スローン ケタリング キャンサー センター |
Ｄｌｌ３を標的とする抗原認識受容体及びその使用
|
|
CA3278900A1
(en)
|
2023-03-31 |
2024-10-03 |
AbelZeta Inc. |
BISPECIFIC CHIMERIC ANTIGENIC RECEPTORS TARGETING CD20 AND BCMA
|
|
CN117169518B
(zh)
*
|
2023-11-03 |
2024-01-19 |
赛德特(北京)生物工程有限公司 |
T淋巴细胞制剂中的cd3抗体残留物的检测方法和试剂盒
|
|
WO2025212519A1
(en)
*
|
2024-04-01 |
2025-10-09 |
Moonlight Bio, Inc. |
Dll3 binding proteins and uses thereof
|